SURPASS-2: The head-to-head trial The SURPASS-2 trial is particularly relevant because it tested tirzepatide specifically in people already taking metformin (at least 1,500 mg daily)
for how the drug works, see how tirzepatide works for weight loss
Targeting a Major Risk Factor Obesity is known to increase the risk of developing many chronic diseases, including breast cancer
Can I switch from standard dosing to microdosing
Losing 5 to 10% of body weight, eating whole foods with plenty of fibre, prioritising sleep, and building a regular movement habit meaningfully lowers progression risk
Timeline: What to Expect The following reflects what is observed in the trial and label data , framed as research reference not a promise of individual results, which vary widely